Literature DB >> 16507833

PMS2 mutations in childhood cancer.

Michel De Vos1, Bruce E Hayward, Ruth Charlton, Graham R Taylor, Adam W Glaser, Susan Picton, Trevor R Cole, Eamonn R Maher, Carole M E McKeown, Jill R Mann, John R Yates, Diana Baralle, Julia Rankin, David T Bonthron, Eamonn Sheridan.   

Abstract

Until recently, the PMS2 DNA mismatch repair gene has only rarely been implicated as a cancer susceptibility locus. New studies have shown, however, that earlier analyses of this gene have had technical limitations and also that the genetic behavior of mutant PMS2 alleles is unusual, in that, unlike MLH1 or MSH2 mutations, PMS2 mutations show low heterozygote penetrance. As a result, a dominantly inherited cancer predisposition has not been a feature reported in families with PMS2 mutations. Such families have instead been ascertained through childhood-onset cancers in homozygotes or through apparently sporadic colorectal cancer in heterozygotes. We present further information on the phenotype associated with homozygous PMS2 deficiency in 13 patients from six families of Pakistani origin living in the United Kingdom. This syndrome is characterized by café-au-lait skin pigmentation and a characteristic tumor spectrum, including leukemias, lymphomas, cerebral malignancies (such as supratentorial primitive neuroectodermal tumors, astrocytomas, and glioblastomas), and colorectal neoplasia with an onset in early adult life. We present evidence for a founder effect in five families, all of which carried the same R802-->X mutation (i.e., arginine-802 to stop) in PMS2. This cancer syndrome can be mistaken for neurofibromatosis type 1, with important management implications including the risk of the disorder occurring in siblings and the likelihood of tumor development in affected individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507833     DOI: 10.1093/jnci/djj073

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  24 in total

1.  Genetic testing of children at risk for adult onset conditions: when is testing indicated?

Authors:  N Lwiwski; C R Greenberg; A A Mhanni
Journal:  J Genet Couns       Date:  2008-07-08       Impact factor: 2.537

2.  The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair.

Authors:  Suzanne M Deschênes; Guy Tomer; Megan Nguyen; Naz Erdeniz; Nicole C Juba; Natalia Sepúlveda; Jenna E Pisani; R Michael Liskay
Journal:  Cancer Lett       Date:  2006-10-09       Impact factor: 8.679

Review 3.  The changing landscape of Lynch syndrome due to PMS2 mutations.

Authors:  J Blount; A Prakash
Journal:  Clin Genet       Date:  2018-03-15       Impact factor: 4.438

4.  Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome.

Authors:  Shahid Mahmood Baig; Ambrin Fatima; Muhammad Tariq; Tahir Naeem Khan; Zafar Ali; Mohammad Faheem; Humera Mahmood; Patrick Killela; Matthew Waitkus; Yiping He; Fangping Zhao; Sizhen Wang; Yuchen Jiao; Hai Yan
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

5.  Biochemical and structural characterization of two variants of uncertain significance in the PMS2 gene.

Authors:  Brandon M D'Arcy; Jessa Blount; Aishwarya Prakash
Journal:  Hum Mutat       Date:  2019-01-30       Impact factor: 4.878

6.  Cancer incidence among the south Asian and non-south Asian population under 30 years of age in Yorkshire, UK.

Authors:  M van Laar; P A McKinney; R C Parslow; A Glaser; S E Kinsey; I J Lewis; S V Picton; M Richards; G Shenton; D Stark; P Norman; R G Feltbower
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

Review 7.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

8.  Cerebral primitive neuroectodermal tumor in an adult with a heterozygous MSH2 mutation.

Authors:  Alexander F Jeans; Ian Frayling; Bharat Jasani; Lucy Side; Claire Blesing; Olaf Ansorge
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

9.  Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.

Authors:  Susanne Magnusson; Ake Borg; Ulf Kristoffersson; Mef Nilbert; Thomas Wiebe; Håkan Olsson
Journal:  Fam Cancer       Date:  2008-05-15       Impact factor: 2.375

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.